Dynavax Technologies Corporation (DVAX)

Market Cap	1.51B
Revenue (ttm)	733.26M
Net Income (ttm)	320.63M
Shares Out	127.59M
EPS (ttm)	2.29
PE Ratio	5.17
Forward PE	6.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,914,456
Open	11.81
Previous Close	11.78
Day's Range	11.71 - 12.00
52-Week Range	7.26 - 17.48
Beta	1.43
Analysts	Buy
Price Target	23.66 (+99.83%)
Earnings Date	Feb 27, 2023

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Ryan Spencer
• Employees: 311
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX

Analyst Forecast

According to 12 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $23.66, which is an increase of 99.83% from the latest price.

Price Target

$23.66

(99.83% upside)

Analyst Consensus: Buy